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Objectives: Establish the Compliance Questionnaire Rheumatology (CQR) poten-
tial value as a predictive adherence tool by identifying similarities, differences 
and overall relationship between the CQR and the Morisky Medication Adherence 
Scale (MMAS-4). MethOds: Patients residing in the United States completed a self-
administered, Internet-based questionnaire in the fall of 2011. Patients self-reported 
a diagnosis of rheumatoid arthritis (RA). The cross sectional survey included the 
CQR, MMAS-4 and extensive treatment and demographic patient level data. CQR 
predicts patients that are likely to be adherent at 50%, 60%, 75%, 80%, 85%, 90% or 
95% levels. The MMAS-4 is scored from 0-4, with zero equal to perfect adherence. 
Frequency distributions were compared. Linear models looked at: inter-item cor-
relations, CQR score thresholds optimally differentiating adherent vs. non-adherent 
on MMAS-4, and ordinary least squares (OLS) analysis of the ability of the CQR to 
predict MMAS-4 scores. Results: Survey respondents were 76.2% female, 86.2% 
Caucasian, with mean age 56.4 years. Frequency distributions of the CQR and 
MMAS-4 were similar. The CQR provided much more detail at high adherence levels, 
and hence appears more discriminative in these patients. Comparing dichotomous 
adherent/non-adherent results, the optimal CQR threshold for predicting “adher-
ent patients” from MMAS-4, was 60%. Correlation between MMAS-4 and CQR was 
0.40. CQR scores can predict MMAS-4 scores, although the relationship appears 
weak. cOnclusiOns: Compared with MMAS-4, the CQR scale appears to be more 
sensitive at high levels of adherence. The CQR appears to be useful as a predictive 
tool. It does not require claims-based data to assess historical non-adherence, and 
so may be a useful alternative. These results warrant further exploration of the 
CQR as a way to stream rheumatology patients into appropriate treatment, based 
on their potential to be non-adherent.
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Objectives: The aim of this study is to assess adherence among patients attended 
by the Secretary of State for Health of Minas Gerais (SES / MG) between 2008 and 2010 
with a diagnosis of osteoporosis and describe the cost of non-adherence to treat-
ment. MethOds: A retrospective cohort study from a database for administrative 
purposes of the SES / MG was made. Selected patients with a diagnosis of osteoporo-
sis in postmenopausal, with at least three records of dispensing drugs and age equal 
to or greater than 40 years. We calculated adherence to treatment considering the 
range of dispensing drugs. Then we proceeded to calculate the cost of non-adher-
ence from demographics and cost in Minas Gerais, Brazil. Results: 3905 patients 
were taking alendronate sodium distributed by Unified Health System Adherence 
to treatment of osteoporosis in Minas Gerais was 80 % and 20 % of irregular adher-
ence. Non-adherence to treatment increases by 20,4% the total cost of osteoporosis, 
considering pharmacological treatment and hospital treatment. cOnclusiOns: 
Adherence to treatment is an important component of treatment effectiveness. 
Poor adherence is related to high treatment costs and high incidence of osteoporo-
tic fractures. The use of administrative databases allows the evaluation of health 
programs, especially programs for dispensing medicines. Measures that increase 
adherence to drug treatment should be taken to reduce the costs and improve the 
effectiveness of osteoporosis treatment.
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Objectives: i) estimate the MCID for EQ-5D in patients with chronic widespread 
pain; ii) estimate the MECD for patients undergoing cognitive behavior therapy 
(CBT), prescribed exercise therapy (EX), and combination therapy, i.e. cognitive 
behavior therapy and prescribed exercise together (COMB). MethOds: Using data 
from a multi-center RCT, MCID was estimated through regression analysis and ROC 
curves. Moreover, average change, minimum detectable change and change dif-
ference approaches were applied. The minimum cost-effective difference (MCED) 
for the three patients’ subgroups allocated to each of the active treatments of the 
trial was estimated through ROC curve approach and through regression analysis. 
The MCED was computed using a threshold of £20,000-£30,000 per QALY as cost-
effectiveness anchor. Ordinary least squares was used in regression analysis while 
ROC were estimated based on logistic analysis Results: Estimates of MCID range 
between .05 and .33. Adopting a cost-effectiveness threshold of £20,000/QALY, 
the MCED was equal to .226, .062 and .104, for CBT, EX and COMB respectively. 
Adopting a cost-effectiveness threshold of £30,000/QALY, the MCED equaled .315, 
.067 and .119, for CBT, EX and COMB, respectively. However, estimates were sensi-
tive to the choice of the anchor and the estimation method. cOnclusiOns: The 
minimal important difference (MID) represents the smallest amount of benefit 
that the patient can recognize and value. It is useful in the design of clinical trials 
for sample size calculations and in the interpretation of results. However, it does 
not help in the allocation of health care resources. Minimum cost-effective dif-
ference (MCED) can be used to bridge MCID and cost-effectiveness, being defined 
as the smallest improvement in the HR-Qol instrument associated with a cost-
effective outcome. MCED allows understanding whether the minimum change 
perceived as meaningful is cost-effective, given a certain acceptability threshold. 
Objectives: This study reports real-world utilization patterns observed for rheuma-
toid arthritis (RA), psoriatic arthritis (PSA), and ankylosing spondylitis (AS) patients 
treated with golimumab (GLM). MethOds: Patients with an ICD-9 code for RA, PSA, 
or AS receiving ≥ 2 fills of GLM as their first biologic medication (bionaive) or most 
recent biologic medication (bio-experienced) were identified between 1/1/2008 and 
12/31/2010 in a large health care claims dataset (Truven Health). Patient characteris-
tics and refill patterns were summarized using descriptive statistics .The proportion 
of adherent refills was calculated as the number of refills occurring between 21and 
38 days from a previous fill divided by the total refill intervals. Results: A total of 
1,515 patients with ≥ 2 GLM fills and a diagnosis of RA (n= 1,036), PSA (n= 325) or AS 
(n= 154) were identified in the database. Median age was: RA 52 years; PsA 50 years; 
AS 47 years. The majority were bio-experienced (RA 72%; PsA 79%; AS 79%). A total 
of 13,738 GLM refills were observed (RA 9,398; PsA 2,961; AS 1,369). The number of 
refills per patient ranged from 2 to 34 with a mean (SD) of 10.1 (7.25) and median 
of 8. The mean (SD) interval for all refills was 34.8±13.0 days; median was 31 days. 
Median refill interval for RA, PsA and AS was 31 days in bio-experienced subgroups 
and 32 days for bionaive subgroups. The proportion of adherent refills overall was 
78%; (RA 79%; PSA 76%; AS 78%). The proportion of adherent refills appeared similar 
for bionaive and bioexperienced patients except in the AS group (bionaive 73.8%; 
bioexperienced 79.3%). cOnclusiOns: This retrospective observational study con-
firms earlier findings that GLM is utilized largely in patients who have used other 
biologic medications. A high proportion of GLM-treated patients were adherent to 
refilling medication and median refill intervals occurred as recommended in the 
GLM prescribing information.
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Objectives: To evaluate patient characteristics and real-world treatment patterns 
of subcutaneous anti-TNF medications for patients enrolled in Humana’s commer-
cial and Medicare patient populations. MethOds: Adult patients (aged ≥ 18 years) 
with ≥ 2 fills of index biologic (adalimumab (ADA), certolizumab (CTZ); etanercept 
(ETA) or golimumab (GLM)) in the post-index period, and continuous eligibility for ≥ 6 
months pre- and 12 months post-index were identified in health care claims. Patient 
age, gender, RxRisk-V score, biologic use and disease modifying anti-rheumatic 
drug (DMARD) use history in the pre-index period were summarized. Utilization 
measures included monthly biologic dose, refill interval, proportion of adherent fills 
(refilled ± 7 days of expected), and proportion of patients with 100% refill adherence. 
Descriptive statistics (mean, SD, n, %), one-way analysis of variance (continuous 
variables), and chi-squared tests (categorical variables) were employed. Results: 
3,568 ADA, 287 CTZ, 3,625 ETA, and 158 GLM patients were studied. The CTZ and 
GLM groups were significantly younger than all others (p< 0.001). The GLM group 
had a higher proportion with prior biologic use (58.2%) vs. ADA (11.1%), CTZ (34.1%), 
and ETA (4.9%); (p< 0.0001). The GLM group had higher mean Rx Risk-V scores as 
compared to ETA (6.51±3.47 vs. 5.94±3.14, respectively; p< 0.05) and had higher pro-
portions of patients with pre-index DMARD use (71.5%) vs. ADA (57.1%), CTZ (54.4%) 
and ETA (52.1%); (p< 0.001). The proportion of patients with 100% of compliant refills 
was significantly greater in the GLM group (39.9%) than ADA -28.6%; CTZ-21.6%; 
ETA-27.3%; p< 0.001) and was statistically lower in the CTZ group as compared to 
all others (p< 0.05). cOnclusiOns: A number of statistically significant differences 
were identified. Golimumab use was associated with a higher proportion of patients 
achieving 100% refill compliance compared to other subcutaneous anti-TNF medica-
tions. The implications of differences in clinical and demographic characteristics 
and medication adherence on patient outcomes require further exploration.
PMS51
treatMent PerSiStenCe With CoMBination VerSuS MonotheraPy in 
CoMMerCially inSured PatientS With rheuMatoid arthritiS
Shah N.1, Bonafede M.M.2, Chastek B.3, Thomson E.2, Song R.3, Harrison D.J.1
1Amgen, Inc, Thousand Oaks, CA, USA, 2Truven Health Analytics, Cambridge, MA, USA, 
3OptumInsight, Eden Prairie, MN, USA
Objectives: To study 1-year treatment persistence among patients with rheuma-
toid arthritis (RA), initiating biologics (etanercept or adalimumab) with or without 
non-biologic disease modifying anti-rheumatic drugs (NbDMARDs). MethOds: 
Adult (≥ 18 years) patients with RA newly treated with etanercept or adalimumab 
with ≥ 360 days continuous enrolment before and after their first (index) biologic 
claim were identified in the MarketScan® Research Databases (Jan 1, 2010-Dec 31, 
2011) and the Optum Research Database (Jan 1, 2009-Oct 1, 2011). Patients with a 
claim for a biologic in the 360 days pre-index or treated with biologics for conditions 
other than RA were excluded. Monotherapy patients met the following criteria at 
index: 1) Initiated monotherapy; no claim for a NbDMARD 360 days pre- and up to 30 
days post-index or 2) Switched to monotherapy; ≥ 1 claim for a NbDMARD between 
day -360 and -30 (pre-index) and no claims for a NbDMARD between day -29 and 
+30. Combination therapy patients met the following criteria: 1) Initiated combi-
nation therapy; no claims for NbDMARDs from day -360 to -30 and ≥ 1 claim for a 
NbDMARD from day -29 to +30 or 2) Switched to combination therapy; ≥ 1 claim for 
a NbDMARD between day -360 and -30, and another claim for a NbDMARD from day 
-29 to +30. Persistence was defined as the number of days from the index date until 
the earlier of a 45-day gap in therapy or a switch to another biologic. Results: Of 
6,626 patients in the MarketScan and 2,426 patients in the Optum databases, 35.7% 
and 36.9% were on biologic monotherapy respectively. Persistence was similar in 
both databases and higher with combination therapy (Truven/Optum: 45.1%/48.6% 
etanercept, 42.6%/47.0% adalimumab) than with monotherapy (Truven/Optum: 
35.5%/43.1% etanercept, 35.1%/44.0% adalimumab). cOnclusiOns: Combination 
therapy was associated with greater persistence than biologic monotherapy.
